Testing two new medications together for hard-to-treat blood cancer

Plain-English translation of NCT05927571 on ClinicalTrials.gov ↗ · Source last updated July 2026 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This clinical trial is testing a combination of two new medications called and in people whose multiple myeloma (a blood cancer) has returned or is no longer responding to prior treatments. Researchers want to learn whether giving these two medications together is safe and how well this treatment works. This is an early-stage study designed to find the right doses and confirm that the combination is tolerable.

Multiple myeloma can become resistant to standard treatments, leaving patients with few options. This trial is exploring whether combining two different types of targeted medications might help people whose cancer has progressed despite previous therapy.

Do you qualify?

You likely qualify if…

you have been diagnosed with relapsed or refractory multiple myeloma according to standard medical criteria
you are in good enough overall health to tolerate the study treatment (ECOG performance status of 0 or 1)
you have never received either of these two medications before
you are willing to use contraception if you are able to become pregnant, or use a condom if male
you have not had an allogeneic stem cell transplant in the past

You likely don't qualify if…

you have a history of autoimmune disease or certain neurological conditions like progressive multifocal leukoencephalopathy
you have active or chronic infections such as hepatitis B, hepatitis C, or HIV
you have a personal history of amyloidosis or certain other blood disorders
you have been previously treated with cevostamab or similar medications targeting FcRH5
you have significant heart disease or a history of multiple myeloma that has spread to your central nervous system

What participation looks like

You would receive two medications: one as an intravenous infusion (into a vein) and one as a subcutaneous injection (under the skin). Before reaching your assigned doses, you would have a step-up dosing period to help your body adjust. You would then continue receiving the treatment until your cancer progresses, you experience unacceptable side effects, or you complete up to one year of treatment. Throughout the trial, you would have regular visits for blood work, scans, and check-ins with the research team to monitor your response and any side effects.

AI-generated summary from trial data · Jun 4, 2026 · Not medical advice

Trial locations(14 sites)

Australia

Royal Prince Alfred Hospital, Camperdown, New South Wales

Calvary Mater Newcastle, Waratah, New South Wales

Royal Adelaide Hospital;Haematology Clinical Trials Unit, Adelaide, South Australia

St. Vincent's Hospital Melbourne, Melbourne, Victoria

The Alfred Hospital, Prahan, Victoria